1. Home
  2. APRE vs NAAS Comparison

APRE vs NAAS Comparison

Compare APRE & NAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • NAAS
  • Stock Information
  • Founded
  • APRE 2006
  • NAAS 2019
  • Country
  • APRE United States
  • NAAS China
  • Employees
  • APRE N/A
  • NAAS N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • NAAS Other Specialty Stores
  • Sector
  • APRE Health Care
  • NAAS Consumer Discretionary
  • Exchange
  • APRE Nasdaq
  • NAAS Nasdaq
  • Market Cap
  • APRE 10.0M
  • NAAS 8.3M
  • IPO Year
  • APRE 2019
  • NAAS 2017
  • Fundamental
  • Price
  • APRE $1.71
  • NAAS $0.85
  • Analyst Decision
  • APRE Strong Buy
  • NAAS
  • Analyst Count
  • APRE 2
  • NAAS 0
  • Target Price
  • APRE $15.50
  • NAAS N/A
  • AVG Volume (30 Days)
  • APRE 50.9K
  • NAAS 1.6M
  • Earning Date
  • APRE 08-11-2025
  • NAAS 07-23-2025
  • Dividend Yield
  • APRE N/A
  • NAAS N/A
  • EPS Growth
  • APRE N/A
  • NAAS N/A
  • EPS
  • APRE N/A
  • NAAS N/A
  • Revenue
  • APRE $1,284,475.00
  • NAAS $43,258,393.00
  • Revenue This Year
  • APRE N/A
  • NAAS $19.53
  • Revenue Next Year
  • APRE N/A
  • NAAS $151.36
  • P/E Ratio
  • APRE N/A
  • NAAS N/A
  • Revenue Growth
  • APRE 33.27
  • NAAS 50.34
  • 52 Week Low
  • APRE $1.41
  • NAAS $0.60
  • 52 Week High
  • APRE $5.01
  • NAAS $41.80
  • Technical
  • Relative Strength Index (RSI)
  • APRE 52.34
  • NAAS 33.62
  • Support Level
  • APRE $1.48
  • NAAS $0.60
  • Resistance Level
  • APRE $1.91
  • NAAS $0.96
  • Average True Range (ATR)
  • APRE 0.16
  • NAAS 0.14
  • MACD
  • APRE -0.00
  • NAAS -0.01
  • Stochastic Oscillator
  • APRE 63.14
  • NAAS 22.99

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.

Share on Social Networks: